OB/Gyn >
Ovarian Cancer
News, opinions and meeting coverage in obstetrics and gynecology.
FDA Panel Puts Brakes on Anti-PARP Drug
WASHINGTON -- Approval of a PARP inhibitor for patients with advanced ovarian cancer should await results of an ongoing clinical trial that has the potential to answer questions about the drug's safety and efficacy, according to an FDA advisory committee that voted against immediate approval.
Jun 25, 2014